NEWS

In the afternoon of November 4, 2022, at the newly opened Zhangjiang Science Hall, a new landmark in Pudong, Shanghai, Linno Pharmaceuticals Inc. (Linno) hosted R&D day to celebrate its 3rd anniversary, with guest speakers and representatives from leading venture capital funds and multinational pharmaceutical companies.

Over the past three years, Linno has grown from scratch, gradually developed technical capabilities, proprietary enabling technologies, and an expanding product pipeline with global competitiveness. In the opening remarks, Dr. Zhaozhong (Jack) Han, founder and executive chairman of Linno, welcomed guests from venture capitals and multinational pharmaceutical companies to show up in the COVID-19 pandemic time and celebrate the achievements with Linno team. Dr. Han also expressed gratitude to all employees for their passion of innovation, creativity and perseverance. He highlighted that the works over the past three years have not only laid a solid foundation for the well-going pipeline expansion but also created a bright future for collaborative product development with partners. Dr. Han especially thanked investors including ZJ LEADING VC and Zhejiang Puhua Capital for their continuous support, enabling transformation of novel technical and product ideas to realities. He also expressed gratitude to the Zhangjiang PharmValley, the high-tech park governance which has set up a vibrant, resourceful, and innovative environment for biotech startups. 

Dr. Wandong ZHANG, MD/PhD and Professor of University of Ottawa, delivered his keynote speech on Biology of Blood-brain barrier (BBB) and BBB-penetration technologies for CNS-targeted therapeutics. Dr. Hongya PAN, MD/PhD and vice president of research at Linno, updated the audience with recent project progress on a novel BBB-penetrating enzyme replacement therapy for metachromatic leukodystrophy (MLD). Dr. Yong XUE, MD/PhD and medical advisor for Linno, talked about Linno’s next generation pathway-selective complement inhibitor for IgA nephropathy. Dr. Miaomiao HU, a partner from Mirae Asset, delivered a speech on “Trends of biomedical investment in the Pandemic era”, and Dr. Cheng ZHANG, founder and chair of TipLab Patent Office, talked about “patent strategies for biotech startups”.